Skip to content

Exelixis EXEL Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Amgen logo
AmgenAMGN

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Exelixis (EXEL) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $1.96M in Q1 2026.
How has Exelixis's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
Exelixis's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 104.4% year-over-year, from $958K to $1.96M.
What is the long-term trend for Exelixis's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Over 5 years (2020 to 2025), Exelixis's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a 25.9% compound annual growth rate (CAGR), from $12K to $38K.